These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29651371)

  • 1. Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country-Nepal: Cost, Efficacy, and Safety.
    Nepal G; Kharel G; Ahamad ST; Basnet B
    Cureus; 2018 Feb; 10(2):e2178. PubMed ID: 29651371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial.
    Singh N; Almekhlafi MA; Bala F; Ademola A; Coutts SB; Deschaintre Y; Khosravani H; Buck B; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar JJ; Ghrooda E; Poppe AY; Williams H; Field TS; Manosalva A; Siddiqui MM; Zafar A; Imoukhoude O; Hunter G; Shamy M; Demchuk AM; Claggett BL; Hill MD; Sajobi TT; Swartz RH; Menon BK
    Stroke; 2023 Nov; 54(11):2766-2775. PubMed ID: 37800372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion From Intravenous Alteplase to Tenecteplase for Treatment of Acute Ischemic Stroke Across a Large Community Hospital Health System.
    Dittmar E; Wolfel T; Menendez L; Pozo J; Ramirez M; Belnap SC; De Los Rios La Rosa F
    Ann Pharmacother; 2023 Oct; 57(10):1147-1153. PubMed ID: 36688289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations.
    Hailu K; Cannon C; Hayes S
    Am J Health Syst Pharm; 2022 Jun; 79(12):944-949. PubMed ID: 35020806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Ahmed S; Hassan M; Bachuwa G; Al Qasmi M; Bhatt DL
    J Thromb Thrombolysis; 2018 Nov; 46(4):440-450. PubMed ID: 30117036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review.
    Potla N; Ganti L
    Int J Emerg Med; 2022 Jan; 15(1):1. PubMed ID: 34983359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
    Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications.
    Murphy LR; Hill TP; Paul K; Talbott M; Golovko G; Shaltoni H; Jehle D
    Ann Emerg Med; 2023 Dec; 82(6):720-728. PubMed ID: 37178103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke.
    Nguyen CP; Lahr MM; van der Zee DJ; van Voorst H; Roos YB; Uyttenboogaart M; Buskens E
    Eur Stroke J; 2023 Sep; 8(3):638-646. PubMed ID: 37641549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke.
    Walton MN; Hamilton LA; Salyer S; Wiseman BF; Forster AM; Rowe AS
    Ann Pharmacother; 2023 May; 57(5):535-543. PubMed ID: 36004394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.
    Bivard A; Garcia-Esperon C; Churilov L; Spratt N; Russell M; Campbell BC; Choi P; Kleinig T; Ma H; Markus H; Molina C; Hsu C; Tsai CH; Meretoja A; Strbian D; Butcher K; Wu T; Davis S; Donnan G; Levi C; Parsons M
    Int J Stroke; 2023 Jul; 18(6):751-756. PubMed ID: 36655938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of a Tenecteplase Protocol for Treatment of Acute Ischemic Stroke in a Health System.
    Pace A; Wai M; Frye E
    Innov Pharm; 2024; 15(1):. PubMed ID: 38779109
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of dosing errors between tenecteplase and alteplase for management of acute ischemic stroke.
    Ray B; Janzen KM; Curran M; Adamson R; Allen L; Warach S; Daley M
    J Am Pharm Assoc (2003); 2023; 63(2):643-647. PubMed ID: 36623954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke.
    Marè A; Lorenzut S; Janes F; Gentile C; Marinig R; Tereshko Y; Gigli GL; Valente M; Merlino G
    Expert Opin Drug Metab Toxicol; 2024; 20(1-2):25-36. PubMed ID: 38275111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase.
    Checkouri T; Gerschenfeld G; Seners P; Yger M; Ben Hassen W; Chausson N; Olindo S; Caroff J; Marnat G; Clarençon F; Baron JC; Turc G; Alamowitch S;
    Stroke; 2023 Oct; 54(10):2491-2499. PubMed ID: 37622385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenecteplase versus alteplase after acute ischemic stroke at high age.
    Thommessen B; Næss H; Logallo N; Kvistad CE; Waje-Andreassen U; Ihle-Hansen H; Ihle-Hansen H; Thomassen L; Morten Rønning O
    Int J Stroke; 2021 Apr; 16(3):295-299. PubMed ID: 32631157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
    Menon BK; Buck BH; Singh N; Deschaintre Y; Almekhlafi MA; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra S; Gioia LC; Jalini S; Cayer C; Phillips S; Elamin E; Shoamanesh A; Subramaniam S; Kate M; Jacquin G; Camden MC; Benali F; Alhabli I; Bala F; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe A; Sehgal A; Zhang Q; Lethebe BC; Doram C; Ademola A; Shamy M; Kenney C; Sajobi TT; Swartz RH;
    Lancet; 2022 Jul; 400(10347):161-169. PubMed ID: 35779553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
    Coutts SB; Berge E; Campbell BC; Muir KW; Parsons MW
    Int J Stroke; 2018 Dec; 13(9):885-892. PubMed ID: 30035698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
    Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
    Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.